165 related articles for article (PubMed ID: 37732324)
41. Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer.
Lu J; Wu D; Li C; Zhou M; Hao D
J Mol Med (Berl); 2014 Nov; 92(11):1159-68. PubMed ID: 25062964
[TBL] [Abstract][Full Text] [Related]
42. Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer.
Zheng H; Shu T; Zhu S; Zhang C; Gao M; Zhang N; Wang H; Yuan J; Tai Z; Xia X; Yi Y; Li J; Guan Y; Xiang Y; Gao Y
Front Oncol; 2021; 11():725264. PubMed ID: 34604063
[TBL] [Abstract][Full Text] [Related]
43. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
JCO Precis Oncol; 2022 May; 6():e2200085. PubMed ID: 35613413
[TBL] [Abstract][Full Text] [Related]
44. Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy.
Sun J; Bao S; Xu D; Zhang Y; Su J; Liu J; Hao D; Zhou M
Cell Death Dis; 2019 Sep; 10(9):661. PubMed ID: 31506427
[TBL] [Abstract][Full Text] [Related]
45. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
[TBL] [Abstract][Full Text] [Related]
46. Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
Zong H; Zhang J; Xu Z; Pan JN; Wang R; Han J; Jiang M; Ren R; Zang L; Wang H; Cao WM
J Cancer; 2022; 13(4):1119-1129. PubMed ID: 35281878
[No Abstract] [Full Text] [Related]
47. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
Frey MK; Pothuri B
Gynecol Oncol Res Pract; 2017; 4():4. PubMed ID: 28250960
[TBL] [Abstract][Full Text] [Related]
48. Stratification of Homologous Recombination Deficiency-Negative High-Grade Ovarian Cancer by the Type of Peritoneal Spread into Two Groups with Distinct Survival Outcomes.
Schnaiter S; Schamschula E; Laschtowiczka J; Fiegl H; Zschocke J; Zeimet A; Wimmer K; Reimer D
Cancers (Basel); 2024 Jun; 16(11):. PubMed ID: 38893248
[TBL] [Abstract][Full Text] [Related]
49. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
Moretto R; Elliott A; Zhang J; Arai H; Germani MM; Conca V; Xiu J; Stafford P; Oberley M; Abraham J; Spetzler D; Rossini D; Antoniotti C; Marshall J; Shields A; Lopes G; Lonardi S; Pietrantonio F; Tomasello G; Passardi A; Tamburini E; Santini D; Aprile G; Masi G; Falcone A; Lenz HJ; Korn M; Cremolini C
J Natl Cancer Inst; 2022 Feb; 114(2):271-279. PubMed ID: 34469533
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies.
Pokataev I; Fedyanin M; Polyanskaya E; Popova A; Agafonova J; Menshikova S; Tryakin A; Rumyantsev A; Tjulandin S
ESMO Open; 2020; 5(1):e000578. PubMed ID: 33551067
[TBL] [Abstract][Full Text] [Related]
51. Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer.
Kim SJ; Sota Y; Naoi Y; Honma K; Kagara N; Miyake T; Shimoda M; Tanei T; Seno S; Matsuda H; Noguchi S; Shimazu K
Transl Oncol; 2021 Feb; 14(2):100986. PubMed ID: 33340887
[TBL] [Abstract][Full Text] [Related]
52. Genetic characteristics of platinum-sensitive ovarian clear cell carcinoma.
Saito R; Kuroda T; Yoshida H; Sudo K; Saito M; Tanabe H; Takano H; Yamada K; Kiyokawa T; Yonemori K; Kato T; Okamoto A; Kohno T
Jpn J Clin Oncol; 2023 Aug; 53(9):781-790. PubMed ID: 37248674
[TBL] [Abstract][Full Text] [Related]
53. Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
Ni J; Guo W; Zhao Q; Cheng X; Xu X; Zhou R; Gu H; Chen C; Chen X
Front Oncol; 2021; 11():746571. PubMed ID: 35070965
[TBL] [Abstract][Full Text] [Related]
54. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
[TBL] [Abstract][Full Text] [Related]
55. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M
Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868
[TBL] [Abstract][Full Text] [Related]
56. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
57. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
Mutter RW; Riaz N; Ng CK; Delsite R; Piscuoglio S; Edelweiss M; Martelotto LG; Sakr RA; King TA; Giri DD; Drobnjak M; Brogi E; Bindra R; Bernheim G; Lim RS; Blecua P; Desrichard A; Higginson D; Towers R; Jiang R; Lee W; Weigelt B; Reis-Filho JS; Powell SN
J Pathol; 2017 Jun; 242(2):165-177. PubMed ID: 28299801
[TBL] [Abstract][Full Text] [Related]
58. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
59. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
Koole SN; Schouten PC; Hauke J; Kluin RJC; Nederlof P; Richters LK; Krebsbach G; Sikorska K; Alkemade M; Opdam M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; Mom CH; Arts HJG; van Ham M; van Dam P; Vuylsteke P; Sanders J; Horlings HM; van de Vijver KK; Hahnen E; van Driel WJ; Schmutzler R; Sonke GS; Linn SC
Int J Cancer; 2022 Oct; 151(8):1394-1404. PubMed ID: 35583992
[TBL] [Abstract][Full Text] [Related]
60. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
Ter Brugge P; Moser SC; Bièche I; Kristel P; Ibadioune S; Eeckhoutte A; de Bruijn R; van der Burg E; Lutz C; Annunziato S; de Ruiter J; Masliah Planchon J; Vacher S; Courtois L; El-Botty R; Dahmani A; Montaudon E; Morisset L; Sourd L; Huguet L; Derrien H; Nemati F; Chateau-Joubert S; Larcher T; Salomon A; Decaudin D; Reyal F; Coussy F; Popova T; Wesseling J; Stern MH; Jonkers J; Marangoni E
Nat Commun; 2023 Apr; 14(1):1958. PubMed ID: 37029129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
